The Cancer Supportive Care Products Market is on track for consistent growth, with an anticipated year-over-year (y-o-y) increase of approximately 4% in 2020. Increasing incidences of cancer worldwide have amplified the demand for supportive care products that help manage the adverse effects of treatments like chemotherapy. These products play a crucial role in improving the quality of life for patients undergoing cancer treatment.
Key Findings and Market Trends:
- Erythropoietin Stimulating Agents (ESAs) are projected to hold a dominant share of the market, due to their effectiveness in managing chemotherapy-induced anemia. ESAs have become essential in supportive cancer care, helping to address the anemia commonly induced by cancer treatments.
- Distribution Channels: Hospital pharmacies are expected to remain the primary channel for cancer supportive care product sales through 2030, as hospitals continue to be the main point of care for cancer patients.
- Increasing Use in Leukemia Treatment: The usage of cancer supportive care products in treating leukemia is anticipated to grow significantly, as innovations in supportive therapies enhance treatment outcomes for blood-related cancers.
- Regional Outlook: North America is set to lead the global cancer supportive care products market, supported by a well-established healthcare infrastructure, high prevalence of cancer, and substantial investment in cancer care advancements. This region is expected to drive market expansion over the next decade.
As advancements in cancer care continue and awareness about the importance of supportive treatments rises, the cancer supportive care products market is positioned for sustainable growth. The demand for products that address side effects and improve patient outcomes is fueling developments that will shape the future of cancer care globally.
Cancer Supportive Care Products Market Analysis
Growing prevalence of cancer has consistently spurred the demand for cancer treatments such as chemotherapy over the past decade. That said, radiation therapy comes with several side effects that are challenging for cancer patients to confront, while they undergo the course of procedure.
While cancer treatment is significantly progressing, rising incidences of side effects are growing as well that are addressed by cancer supportive care products.
Oncology is among the fastest-growing therapeutic areas (TAs) worldwide, and is projected to capture about 26% of pharmaceutical sales by 2022, with 107 novel drug approvals in 2018 alone.
In addition, the domain is highly competitive – 35% of the industry preclinical pipeline lies in oncology, and leading players have a commercial footprint. This investment and interest is partially driven by rapid development cycles.
Technological intervention in cancer supportive care products has enabled to treat various indications following chemotherapy procedure, as well as chemotherapy-induced nausea, vomiting, anemia, and neutropenia.
The global cancer supportive care products market is currently growing at a sound pace and is expected to experience moderate growth over the forecast period, 2020-2030.
A Comprehensive Full Report
Key Segment
Drug Class
- Nonsteroidal Anti- Inflammatory Drugs
- Anti-Infective
- Anti-Emetics
- Monoclonal Antibodies
- Erythropoietin Stimulating Agents
- Opioid Analgesics
- Bisphosphonates
- Granulocyte Colony Stimulating Factor
Indication
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Leukemia
- Ovarian Cancer
- Melanoma
- Others
Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Compounding Pharmacies
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube